About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropace Inc (NQ: NPCE )

6.290 -0.160 (-2.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neuropace Inc

< Previous 1 2 3 Next >
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q2 2024
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024
NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The Latest Analyst Ratings For NeuroPace
Via Benzinga
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: NeuroPace Q4 Earnings
Via Benzinga
Earnings Preview: NeuroPace
Via Benzinga
A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts
Via Benzinga
NeuroPace Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Breaking Down NeuroPace: 6 Analysts Share Their Views
Via Benzinga
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
Stocks for financial freedom are generational companies that are well-run, growing fast, and focused on the future. 
Via InvestorPlace
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
Expert Ratings for NeuroPace
Via Benzinga
Expert Ratings for NeuroPace
Via Benzinga
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
Cantor Fitzgerald initiated coverage on NeuroPace Inc (NASDAQ: NPCE), a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
NeuroPace's Return On Capital Employed Overview
Via Benzinga
Recap: NeuroPace Q1 Earnings
Via Benzinga
Looking Into NeuroPace's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Alpha Tau Medical Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
People Are Lining Up For Elon Musk's Neuralink Brain Implant — Here's How You Can Invest In Brain Technology Startups
Via Benzinga
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P... 
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.